News Sarepta files controversial Duchenne drug in EU US biotech seeks conditional approval for eteplirsen in EU.
News FDA's Duchenne drug approval greeted with joy, but remains c... FDA will require efficacy evidence.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.